Gui Bin She International Holding Group (GBS)
Market Cap | n/a |
Revenue (ttm) | n/a |
Net Income (ttm) | n/a |
Shares Out | n/a |
EPS (ttm) | n/a |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | n/a |
Open | n/a |
Previous Close | n/a |
Day's Range | n/a |
52-Week Range | n/a |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About GBS
Founded in 2016, Shenzhen GBS Hotel Group is headquartered in Futian CBD, Shenzhen, featuring a compendious French style created by a renowned brand designing company. GBS is positioned as a French-style medium-and-high-end business hotel chain, providing customers with healthy, safe, comfortable, and environmentally friendly accommodations. By providing unique VIP services and first-class ambiance, we strive to create a affordable luxury travel experience for customers, and are committed to forging a national brand model. To date, GBS has dire... [Read more]
News
![](https://cdn.snapi.dev/images/v1/w/h/press19-1599940.jpg)
GBS Inc. Initiates Company Name Change to Intelligent Bio Solutions Inc. (IBSS) and Announces Key Executive Appointments
- Name change to more closely reflect firm's expanding portfolio of intelligent, efficient, convenient and practical noninvasive and drug testing technologies and products -
![](https://cdn.snapi.dev/images/v1/2/i/press16-1568370.jpg)
GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology
NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners a...
![](https://cdn.snapi.dev/images/v1/w/q/press19-1526837.jpg)
GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights
- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition -
![](https://cdn.snapi.dev/images/v1/i/l/conf6-1522514.jpg)
GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31
Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
![](https://cdn.snapi.dev/images/v1/v/w/press6-1450450.jpg)
GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood
NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...
![](https://cdn.snapi.dev/images/v1/s/e/press6-1426978.jpg)
GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus
NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...
![](https://cdn.snapi.dev/images/v1/j/a/press2-1419904.jpg)
GBS INC. Announces Adjournment of 2022 Annual Meeting of Stockholders to July 13, 2022
NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...
![](https://cdn.snapi.dev/images/v1/q/g/press5-1418894.jpg)
GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse
- Intelligent Fingerprinting Limited's commercial-stage, revenue-generating platform technology would provide an expanded product upon which to leverage the existing GBS pipeline - Intelligent Fingerp...
![](https://cdn.snapi.dev/images/v1/9/0/conf13-1376669.jpg)
GBS Inc. to Present at the H.C. Wainwright Global Investment Conference
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at ...
![](https://cdn.snapi.dev/images/v1/r/g/press10-1373268.jpg)
GBS Inc. to Hold Virtual 2022 Annual Shareholder Meeting on Thursday, June 16, 2022, at 4:00pm ET
NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at ...
![](https://cdn.snapi.dev/images/v1/c/4/press1-1366701.jpg)
GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights
- Initiated prospective study to collect coincident samples of oral fluid and blood following IRB approval -
![](https://cdn.snapi.dev/images/v1/1/0/conf10-1350615.jpg)
GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10
Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
![](https://cdn.snapi.dev/images/v1/c/d/press20-1302188.jpg)
GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center
The trial is single center, prospective study to collect coincident samples of oral fluid and blood to evaluate the time-course of glucose
![](https://cdn.snapi.dev/images/v1/y/c/conf4-1265659.jpg)
GBS Inc. to Participate in the Upcoming March Investor Conferences
NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at poi...
![](https://cdn.snapi.dev/images/v1/m/l/press13-1228671.jpg)
GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights
- Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant Funding Award from Australian Government -
![](https://cdn.snapi.dev/images/v1/d/2/conf4-1220641.jpg)
GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10
Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
![](https://cdn.snapi.dev/images/v1/7/m/conf11-1156638.jpg)
GBS Inc. to Participate in the Upcoming January Virtual Investor Conferences
NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at poin...
![](https://cdn.snapi.dev/images/v1/j/z/press6-1147049.jpg)
GBS Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...
GBS Shares Are Rallying On Plans For COVID-19 Antibody Trials After Validation Study
GBS Inc (NASDAQ:GBS) will prepare for clinical trials of its rapid SARS-CoV-2 (COVID-19) Antibody test following the recent successful completion of a clinical validation study. As previously referenc...
![](https://cdn.snapi.dev/images/v1/m/e/press3-1128447.jpg)
GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study
NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...
![](https://cdn.snapi.dev/images/v1/b/t/press18-1104007.jpg)
GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights
– Announced Pre-Submission Package sent to the FDA for its Glucose Biosensor Test –
![](https://cdn.snapi.dev/images/v1/e/h/conf11-1080126.jpg)
GBS Inc. to Present First Quarter 2022 Financial Results and Recent Corporate Update on November 11
Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
![](https://cdn.snapi.dev/images/v1/a/6/press2-1078775.jpg)
GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing
NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...
![](https://cdn.snapi.dev/images/v1/t/e/press5-1054606.jpg)
FDA Pre-Submission for Saliva-Based Glucose Test to Replace Invasive Finger-Prick
SYDNEY, Oct. 19, 2021 /PRNewswire/ -- The iQ Group Global Ltd (NSX.IQG), on behalf of its subsidiary, Life Science Biosensor Diagnostics Pty Ltd (LSBD), is pleased to announce that one of its licensee...
![](https://cdn.snapi.dev/images/v1/m/o/press8-1046877.jpg)
GBS Inc. Announces its Pre-Submission package is with the FDA
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...